REGULATED INFORMATION
PRESS RELEASE

TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – August 7, 2015 – TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by the company Genetrix S.L. (with address at Calle Santiago Grisolía n°2, Parque Tecnológico Madrid, 28760 Tres Cantos, Madrid, Spain), who notifies alone, regarding the crossing above the 3% threshold on July 31, 2015 following the acquisition of shares by Genetrix S.L., after which its participation amounts to 7,712,757 shares (4.59%) (compared to the denominator of 168,189,377 shares). Genetrix S.L. is not controlled.

For further details regarding this notification, we refer to our website: http://www.tigenix.com/en/page/26/shareholders.

Genetrix S.L. acquired the 7,712,757 shares as a result of the closing of the acquisition by TiGenix of Coretherapix on July 31, 2015. These shares are subject to lock-up undertakings for up to 12 months. Part of the shares will be gradually released from the lock-up over the 12-months´ period.

For more information:

Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase II for early rheumatoid arthritis, and has completed a Phase I sepsis challenge trial. Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.